Cartalax vs Dermorphin
A side-by-side research comparison of Cartalax and Dermorphin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cartalax | Dermorphin |
|---|---|---|
| Full name | Cartalax (Ala-Glu-Asp-Gly Cartilage Bioregulator) | Dermorphin (Opioid Heptapeptide) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Research compound (peptide bioregulator) | Research compound |
| Mechanism | As a signal peptide (Ala-Glu-Asp-Gly), it is proposed to regulate gene expression in chondrocytes and connective tissue, supporting cartilage matrix maintenance and anti-inflammatory tissue signaling. | Binds mu-opioid receptors with very high affinity and selectivity, producing potent analgesia. Its unusual D-alanine residue makes it resistant to breakdown, contributing to a much stronger effect than morphine on a per-weight basis. |
| Molecular weight | ~390 Da | 803.9 Da |
| Half-life | Short (peptide) | Short (peptide) |
| Bioavailability | Oral (encapsulated) or subcutaneous | Injection (research) |
| Typical dose | ~1-2 capsules/day or short injectable courses | Not established for human use |
| Frequency | Once daily | Research only |
| Route | Oral capsule or subcutaneous | Injection (research) |
Cartalax reported benefits
- Cartilage/joint tissue support
- Connective tissue maintenance (proposed)
- Anti-inflammatory tissue signaling
- Short course-based protocol
Dermorphin reported benefits
- Potent analgesia (research context)
- High mu-opioid receptor selectivity (research interest)
Related comparisons
Research and educational reference only. Not medical advice.